News | January 10, 2007

AngioSculpt Now Aimed at Stenosis

Jan. 11, 2007 — AngioScore’s flagship product, the AngioSculpt Scoring Balloon Catheter, has received FDA Premarket Approval (PMA) for use in the treatment of hemodynamically significant coronary artery stenosis, including in-stent restenosis and complex type C lesions, for the purpose of improving myocardial perfusion.

With the PMA approval, AngioScore can begin marketing the AngioSculpt in the U.S. for the treatment (as indicated) of coronary artery disease (CAD). The company says that more than one million coronary angioplasty procedures are performed every year in this country, and another 1.5 million procedures are performed worldwide.

AngioSculpt was 510(k) approved in 2005 for balloon dilatation of lesions in infra-popliteal arteries, a key segment of the rapidly growing peripheral artery disease (PAD) market. In addition, the company has also been granted the CE Mark for the AngioSculpt allowing the product to be sold in Europe and the Middle East.

Martin B. Leon, M.D., professor of Medicine at Columbia University and chairman of the Cardiovascular Research Foundation (CRF), served as the principal investigator for the device’s U.S. multicenter clinical trial, a prospective study that evaluated the safety and effectiveness of the AngioSculpt in 200 patients with single or multiple vessel coronary artery disease, in both de novo lesions and in-stent restenosis lesions.

“We are very pleased to have had the opportunity to provide a leadership role in the U.S. clinical trial of the AngioSculpt,” said Dr. Leon. “The results of the clinical trial indicate that the AngioSculpt is a promising new addition for the treatment of coronary artery disease, particularly for challenging lesions and in facilitating precise stent placement and expansion.”

For more information visit

Related Content

Navitian Coronary Microcatheter Receives CE Mark Approval
News | Catheters | February 21, 2019
Navitian, the new coronary microcatheter from iVascular, recently received CE mark approval. The device was approved to...
First U.S. Patients Treated With OrbusNeich Teleport Microcatheter
News | Catheters | January 31, 2019
Cardiovascular Systems Inc. announced that the first patients in the United States were treated using the OrbusNeich...
Merit Medical Acquires Assets of Vascular Insights LLC
News | Catheters | December 18, 2018
Merit Medical Systems Inc. announced that it has acquired substantially all of the assets of Vascular Insights LLC,...
Reflow Medical's Wingman Crossing Catheter Receives FDA Clearance for Coronary Indication
News | Catheters | October 02, 2017
October 2, 2017 — Reflow Medical Inc. announced that the company has received 510(k) clearance from the U.S.
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters | August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
Teleflex, FDA 510k clearance, TrapLiner Catheter, U.S. launch
Technology | Catheters | March 02, 2017
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
Merit Medical Systems, SwiftNINJA Steerable Microcatheter, FDA 510(k) clearance
Technology | Catheters | November 09, 2016
November 9, 2016 — Merit Medical Systems Inc.
VentureMed Group, Flex Scoring Catheter, FDA approval, peripheral arterial disease, PAD, endovascular treatment
Technology | Catheters | July 13, 2016
July 13, 2016 — VentureMed Group Ltd., specializing in devices for the endovascular treatment of...
Roxwood Medical, MicroCross Catheter, full U.S. launch

Image courtesy of Roxwood Medical

Technology | Catheters | January 07, 2016
Roxwood Medical Inc. reported that more than 500 patients have been successfully treated as part of the initial limited...
Overlay Init